arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Voyager Therapeutics, Inc.

VYGR
$1.73 ▼ -0.15 (-8.24%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
50 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
18
Health
Poor
Bearish
auto_awesome

Analytical Summary

Voyager Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $104.7M
Dividend Yield —
Revenue Growth -39.1% ↗
Op. Margin None
ROIC -17.1% →
FCF / Share $-0.43 ↗
Trailing P/E —
Price / Book 0.7x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

50-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$3.17M
↓ -39.1% —
Net Income Profit after all expenses
$-27.94M
↑ +9.9% —
Operating Margin Operating profit as % of sales
-195.2%
↑ +14.7% 0th
FCF / Share Free cash flow per share
$-0.43
↑ +24.0% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
0
Returns ↑
14
Cash Quality ↑
70

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 13 years · 50 quarters